Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
MRNS Marinus Pharmaceuticals
6.530-0.125-1.88%
Close
02/03 16:00 ET
6.600+0.070+1.07%
Post Mkt Price 02/03 17:09 ET
High
6.750
Open
6.600
Turnover
3.12M
Low
6.480
Pre Close
6.655
Volume
470.41K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Marinus Pharmaceuticals Appoints Christine Silverstein to Its Bd of Directors
Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target Cut to $23.00
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) had its price target lowered by SVB Leerink from $27.00 to $23.00 in a research report sent to investors on Monday, Benzinga reports. SVB Leerink cu
SVB Leerink Comments on Marinus Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:MRNS)
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating) – Investment analysts at SVB Leerink cut their FY2023 earnings estimates for shares of Marinus Pharmaceuticals in a report issued on Monday
Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at Royal Bank of Canada
Royal Bank of Canada assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) in a report published on Friday morning, The Fly reports. The firm issued an outperform rating an
SVB Securities Adjusts Price Target on Marinus Pharmaceuticals to $23 From $27, Maintains Outperform Rating
09:16 AM EST, 01/23/2023 (MT Newswires) -- Marinus Pharmaceuticals (MRNS) has an average buy rating and price target range of $12 to $50, according to analysts polled by Capital IQ. Price: 5.7, Change
Marinus Pharmaceuticals Is Maintained at Outperform by SVB Leerink
Marinus Pharmaceuticals Price Target Cut to $23.00/Share From $27.00 by SVB Leerink
SVB Leerink Maintains Outperform on Marinus Pharma, Lowers Price Target to $23
SVB Leerink analyst Marc Goodman maintains Marinus Pharma with a Outperform and lowers the price target from $27 to $23.
Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Royal Bank of Canada
Analysts at Royal Bank of Canada initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) in a report issued on Friday, The Fly reports. The firm set an "outperform" rating
Cosmos, InMed Top Healthcare Gainers; Innovative, Panbela Lead Losers' Pack
Company Overview
More
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
CEO： Dr. Scott Braunstein, M.D.
Market： NASDAQ
Listing Date： 07/31/2014
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet